(Press-News.org) Liver cancer cells thrive on fat, posing a serious risk of cancer diagnosis for millions of people living with fatty liver disease. But researchers at McMaster University in collaboration with Espervita Therapeutics have developed a promising new treatment that helps the immune system attack and destroy these tumours.
The discovery, detailed in a study published in Nature on July 30, 2025, opens new possibilities for slowing tumour growth and empowering the body’s natural defences. This is particularly important, as current treatments for liver cancer are not very effective, with fewer than one in five people surviving longer than five years.
“This is one of the first studies to show that targeting metabolism in tumours can enable the immune system to kill liver cancer cells, and opens the door to more effective prevention and treatment strategies for this deadly disease,” says professor Gregory Steinberg, who is co-director of the Centre for Metabolism, Obesity and Diabetes Research at McMaster and senior author of the study.
Researchers focused on an enzyme called ATP citrate lyase (ACLY), which plays a key role in converting sugar into fat, and designed a drug that inhibits or “switches off” the enzyme selectively in the liver. The result was promising: tumours were detected and killed. Even more exciting for the researchers was an unexpected discovery that the immune response was not triggered by the widely-known cancer-fighting T cells, but by their lesser-known cousin: B cells.
“While T cells are widely recognized for their role in fighting cancer, the contribution of B cells has been less well understood. Our findings highlight a novel and previously underappreciated connection between cancer metabolism and B cell–mediated tumour immunity,” says Jaya Gautam, lead author and research associate in McMaster’s Department of Medicine.
Fatty liver disease, formally known as metabolic dysfunction–associated steatotic liver disease (MASLD), affects approximately eight million Canadians. Of those, 20 per cent will develop metabolic dysfunction-associated steatohepatitis (MASH), a specific, more severe form of fatty liver disease, that dramatically increases the risk of developing liver cancer.
The drug that inhibits the ACLY enzyme is called EVT0185, and was administered in mice with MASH and liver cancer. Mice that were given the drug had fewer tumours that were more vulnerable to attack by immune cells, particularly B cells.
Researchers note more work is needed to better understand how blocking ACLY in tumours enhances the effects of the immune system, and if a similar B cell-driven response could occur in humans and other types of cancer.
The study was supported by the Canadian Institutes of Health Research Foundation Grant and Espervita Therapeutics, of which several of the authors are shareholders.
Interested in covering the study?
Senior author Gregory Steinberg can be reached directly at gstein@mcmaster.ca.
Lead author Jaya Gautam can be reached directly at gautamj@mcmaster.ca.
For any other information or to obtain a copy of the embargoed study, contact Adam Ward, media relations officer with McMaster University's Faculty of Health Sciences, at warda17@mcmaster.ca. END
McMaster research offers promising new treatment for liver cancer
2025-07-30
ELSE PRESS RELEASES FROM THIS DATE:
Most US adults have hearts older than their actual age. How old is yours?
2025-07-30
CHICAGO --- Most U.S. adults have a “heart age” several years older than their chronological age — sometimes by more than a decade. And that gap is wider among men and among those with lower incomes or education or who identify as Black or Hispanic, according to a new study led by Northwestern Medicine.
As part of the study, the Northwestern scientists created a free online tool that calculates a person’s “heart age” based on their risk for cardiovascular disease, using routine health data such as blood pressure, cholesterol levels and whether ...
JMIR Biomedical engineering invites submissions on voice phenotyping and vocal biomarkers
2025-07-30
(Toronto, July 30, 2025) JMIR Publications invites submissions to a new theme issue titled “Voice Phenotyping and Vocal Biomarkers” in its open access journal JMIR Biomedical Engineering. The premier, peer-reviewed journal is indexed in PubMed, PubMed Central, Scopus, DOAJ, Sherpa/Romeo, and EBSCO/EBSCO Essentials.
This Call for Papers is seeking high-quality submissions for a new e-collection on a leading-edge field that uses voice and speech analysis to advance the detection, monitoring, and treatment of health conditions.
This e-collection focuses on acoustic and ...
The metabolic dialogue between intratumoral microbes and cancer: implications for immunotherapy
2025-07-30
The tumor microenvironment (TME) represents a highly complex system that encompasses cellular components (such as cancer cells, stromal cells, and immune cells) and non-cellular components (such as blood vessels and signaling molecules)[1-3]. These diverse components engage in complex interactions with tumor cells and undergo dynamic changes during tumor progression. Specifically, intratumoral microbial metabolites play an important role on the TME. The metabolic products of these microorganisms encompass a range of bioactive molecules, including lactate, amino acids, short-chain fatty acids (SCFAs), bile acids, trimethylamine N-oxide, and inosine. These metabolites, ...
Demographic data supporting FDA authorization of AI devices for Alzheimer disease and related dementias
2025-07-30
About The Study: Transparency of evidence supporting Food and Drug Administration (FDA) authorization of artificial intelligence (AI)- and machine learning -based devices for Alzheimer disease and related dementias was limited, precluding effective evaluation of training and validation dataset representativeness. Disease status (i.e., dementia type and distribution), age, and sex were reported for fewer than half of devices, while race and ethnicity data were rarely disclosed, raising uncertainty about real-world generalizability and clinical accuracy in intended populations.
Corresponding Author: To contact the corresponding ...
How the common fungus Candida albicans colonizes the gut
2025-07-30
About 80% of people have the fungus Candida albicans in their gut. Although most of the time it persists unnoticed for years causing no health problems, C. albicans can turn into a dangerous microbe that causes serious diseases in many organs, including the urinary tract, lungs and brain. Understanding how this fungus colonizes the gut is key to preventing it from becoming harmful.
Working with a mouse model, researchers at Baylor College of Medicine and international collaborators have discovered unexpected factors that help C. albicans ...
How are coastal New Jersey communities communicating hazards of climate change?
2025-07-30
Recent climate-related crises — from severe storms and flooding to extreme heat — have raised new questions about how local governments communicate the risk of these crises and what they are doing to keep their citizens safe. To better understand what this communication looks like at local level, and the factors that may be shaping it, researchers from Drexel University analyzed climate resilience planning information available on the public-facing websites of 24 coastal communities in New Jersey that are contending with the effects of sea level rise. Their report, recently published in the Journal of Extreme Events, ...
AI-based breast cancer risk technology receives FDA Breakthrough Device designation
2025-07-30
A new technology that harnesses AI to analyze mammograms and improve the accuracy of predicting a woman’s personalized five-year risk of developing breast cancer has received Breakthrough Device designation from the Food and Drug Administration (FDA). Developed by researchers at Washington University School of Medicine in St. Louis, the software has been licensed to Prognosia Inc., a WashU startup company.
The system analyzes mammograms to produce a risk score estimating the likelihood that a woman will develop breast cancer over the next five years. The technology is ...
Young men with passive approach to news tend to believe medical misinformation
2025-07-30
True or false?
“It is safe to take an over-the-counter medicine to help you sleep, even if you are drunk on alcohol.”
“Driving while high on THC (cannabis) is safe.”
“Using psychedelics is safe for everyone.”
None of those statements is true. But young men who take a passive approach to news and information—consuming whatever flows over their social media transoms—were likely to believe them in a national survey conducted by Washington State ...
Announcing Zuber Lawler as a Sponsor of ARDD 2025
2025-07-30
The University of Copenhagen is excited to announce Zuber Lawler as a Sponsor of the 12th Aging Research & Drug Discovery Meeting, the world's largest conference on aging research in the biopharmaceutical industry that will transpire on August 25 - August 29, 2025 on-site at the Ceremonial Hall, University of Copenhagen, and online.
“Zuber Lawler demonstrates meticulous attention to detail with a client-first mentality… They offer personalized care from highly intelligent and creative counsel… ...
Is this what 2,500-year-old honey looks like?
2025-07-30
Decades ago, archaeologists discovered a sticky substance in a copper jar in an ancient Greek shrine. And until recently, the identity of the residue was still murky — is it a mixture of fats, oils and beeswax or something else? Researchers publishing in the Journal of the American Chemical Society have reanalyzed samples of the residue using modern analytical techniques and determined that it’s likely the remains of ancient honey — a conclusion previous analyses rejected.
Honey was an important substance in the ancient world, sometimes left in shrines as offerings ...